HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Papers In Press, published online ahead of print May 1, 2007
J. Lipid Res., doi:10.1194/jlr.P600011-JLR200

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: P600011-JLR200v1 48/5/1190    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zheng, C. Articles by Sacks, F. M. Search for Related Content PubMed PubMed Citation Articles by Zheng, C. Articles by Sacks, F. M. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 48, 1190-1203, May 2007
Copyright © 2007 by American Society for Biochemistry and Molecular Biology

Patient-Oriented Research

Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions

Chunyu Zheng^*, Christina Khoo^1,*, Katsunori Ikewaki and Frank M. Sacks^2,*

^* Department of Nutrition, Harvard School of Public Health, Boston, MA 02115
Division of Cardiology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan 105-8461

The online version of this article (available at http://www.jlr.org) contains supplementary data.

Published, JLR Papers in Press, February 21, 2007.

¹ Present address of C. Khoo: Hill's Pet Nutrition, Topeka, KS 66617.

² To whom correspondence should be addressed. e-mail: fsacks{at}hsph.harvard.edu

ABSTRACT

The atherogenicity theory for triglyceride-rich lipoproteins (TRLs; VLDL + intermediate density lipoprotein) generally cites the action of apolipoprotein C-III (apoC-III), a component of some TRLs, to retard their metabolism in plasma. We studied the kinetics of multiple TRL and LDL subfractions according to the content of apoC-III and apoE in 11 hypertriglyceridemic and normolipidemic persons. The liver secretes mainly two types of apoB lipoproteins: TRL with apoC-III and LDL without apoC-III. Approximately 45% of TRLs with apoC-III are secreted together with apoE. Contrary to expectation, TRLs with apoC-III but not apoE have fast catabolism, losing some or all of their apoC-III and becoming LDL. In contrast, apoE directs TRL flux toward rapid clearance, limiting LDL formation. Direct clearance of TRL with apoC-III is suppressed among particles also containing apoE. TRLs without apoC-III or apoE are a minor, slow-metabolizing precursor of LDL with little direct removal. Increased VLDL apoC-III levels are correlated with increased VLDL production rather than with slow particle turnover. Finally, hypertriglyceridemic subjects have significantly greater production of apoC-III-containing VLDL and global prolongation in residence time of all particle types. ApoE may be the key determinant of the metabolic fate of atherogenic apoC-III-containing TRLs in plasma, channeling them toward removal from the circulation and reducing the formation of LDLs, both those with apoC-III and the main type without apoC-III.

Supplementary key words kinetics • stable isotopes • apolipoprotein B-100 • apolipoprotein E • low density lipoprotein

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Kawakami, M. Osaka, M. Tani, H. Azuma, F. M. Sacks, K. Shimokado, and M. Yoshida Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell Dysfunction Circulation, August 12, 2008; 118(7): 731 - 742. [Abstract] [Full Text] [PDF]

				C. Zheng, C. Khoo, J. Furtado, K. Ikewaki, and F. M Sacks Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III Am. J. Clinical Nutrition, August 1, 2008; 88(2): 272 - 281. [Abstract] [Full Text] [PDF]

				P. G. Scheffer, T. Teerlink, J. M. Dekker, G. Bos, G. Nijpels, M. Diamant, P. J. Kostense, C. D. A. Stehouwer, and R. J. Heine Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study Clin. Chem., August 1, 2008; 54(8): 1325 - 1330. [Abstract] [Full Text] [PDF]

				J. S. Millar, M. E. Brousseau, M. R. Diffenderfer, P. H. R. Barrett, F. K. Welty, J. S. Cohn, A. Wilson, M. L. Wolfe, C. Nartsupha, P. M. Schaefer, et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism J. Lipid Res., March 1, 2008; 49(3): 543 - 549. [Abstract] [Full Text] [PDF]